In this study, the EGFR inhibitor, gefitinib, and the EGFR and HER2 dual inhibitor, lapatinib, combined with the IGF-1R inhibitor, linsitinib, were performed to treat four ESCC cells, and their effects on cell viability, cell cycle distribution, cell apoptosis, cell invasion, and migration as well as the in vivo efficacy in the transplanted mouse model were measured. Here, IGF1R is linked to esophageal squamous cell carcinoma.